文献速递其他结缔组织病

抗HMGCR免疫介导坏死性肌病中早期与晚期启动静脉注射免疫球蛋白治疗的获益比较

Benefits of Early Versus Late Initiation of Intravenous Immunoglobulin in the Treatment of Patients With Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Immune-Mediated Necrotizing Myopathy.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2024-09-11

回顾性纳入俄勒冈健康与科学大学肌炎中心2016年9月至2022年10月诊断的31例抗HMGCR免疫介导坏死性肌病成人患者,比较诊断后6个月内(非延迟组19例)与6个月后(延迟组12例)启动IVIG的疗效。延迟组诊断至IVIG时间显著更长(P<0.001),非延迟组12个月MMT8显著改善(P<0.001),TIS在3、6、12个月均优于延迟组(P=0.002、P=0.019、P=0.001);延迟组7例12个月时遗留需助行器或轮椅的永久肌无力,非延迟组无。

要点

  • 诊断后6个月内启动IVIG者12个月MMT8显著改善(P<0.001)。
  • 非延迟组TIS在3、6、12个月均优于延迟组(P=0.002、0.019、0.001)。
  • 延迟组7例12个月时遗留需助行器或轮椅的永久肌无力,非延迟组无。

核心结论

  • 作者认为,尽管结果存在局限性,IVIG可能成为抗HMGCR免疫介导坏死性肌病患者早期积极诱导方案的 valuable addition,尤其适用于需轮椅或助行器的中重度无力者。
  • 作者认为,延迟IVIG治疗可能导致永久残留无力和长期残疾。

研究设计与样本

  • 俄勒冈健康与科学大学肌炎中心的回顾性病历回顾。
  • 纳入2016年9月至2022年10月诊断的31例抗HMGCR免疫介导坏死性肌病成人患者。
  • 按诊断后6个月内(非延迟组19例)或6个月后(延迟组12例)启动IVIG分组。
  • 诊断依据2016年欧洲神经肌肉病中心标准:血清CK升高、近端肌无力和抗HMGCR抗体三项均具备。
  • 采用2016年美国风湿病学会/EULAR肌炎反应标准中的简化总改善评分(TIS)评估治疗反应。

主要发现

  • 延迟组诊断至IVIG治疗时间显著长于非延迟组(P<0.001)。
  • 0个月时非延迟组9例(47%)需助行器或轮椅,延迟组8例(66%)需助行器或轮椅。
  • 非延迟组12个月时MMT8显著改善(P<0.001)。
  • 两组3、6、12个月平均血清CK值无显著差异。
  • 非延迟组TIS改善优于延迟组:3个月P=0.002、6个月P=0.019、12个月P=0.001;延迟组7例12个月时遗留需助行器或轮椅的永久肌无力,非延迟组无。

关键数值与推荐

  • 抗HMGCR免疫介导坏死性肌病诊断依据2016年欧洲神经肌肉病中心标准,需同时具备血清CK升高、近端肌无力和抗HMGCR抗体。
  • 治疗反应评估采用2016年美国风湿病学会/EULAR肌炎反应标准中的简化总改善评分(TIS)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者述本研究结果存在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: No clinical trials have been conducted to establish optimal and effective treatment in patients with immune-mediated necrotizing myopathy (IMNM), which can have a refractory course with increased morbidity from permanent muscle damage, especially in patients who experience delay in diagnosis and treatment. A subset of autoimmune necrotizing myopathy is associated with antibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). Treatment involves withdrawing statins and using a combination of immunosuppressant and immunomodulatory treatment. Our study aims to provide longitudinally collected data on outcomes of early versus late initiation of intravenous Ig (IVIG) using our myositis center cohort of patients with anti-HMGCR IMNM. METHODS: We conducted a retrospective chart review of 31 adult patients of the Oregon Health and Science University Myositis Center who were diagnosed with anti-HMGCR IMNM from September 2016 through October 2022 and reviewed physical examination, serologic laboratory data, and their treatment including prednisone reception as well as treatment response at 0 (the evaluation immediately before IVIG initiation), 3, 6, and 12 months on treatment. We divided this cohort into those who received IVIG at or before six months after receiving the diagnosis of anti-HMGCR IMNM and refer this as the cohort with nondelayed treatment, and those who received IVIG after six months following their diagnosis, which we referred to as the cohort with delayed treatment. Diagnosis of anti-HMGCR IMNM was defined as per the 2016 European Neuromuscular Centre criteria as having all three of elevated serum creatine kinase (CK), proximal muscle weakness, and anti-HMGCR antibodies. We evaluated the response to treatment by using a limited total improvement score (TIS) as per 2016 American College of Rheumatology/EULAR myositis response criteria. RESULTS: Among the 31 total patients, 19 were included within the cohort with nondelayed treatment, and 12 within the cohort with delayed treatment. The two cohorts had a comparable amount of time between the onset of symptoms and diagnosis; however, the cohort with delayed treatment had a significantly longer time between diagnosis and IVIG treatment (P < 0.001). At disease onset, cohorts had a comparable serum CK (P > 0.999), but patients with delayed treatment had an expected lower serum CK (P = 0.016) at the 0-month time point. At the 0-month time point, nine of the patients with nondelayed treatment (47%) required the use of a walker or wheelchair, whereas eight of the cohort with delayed treatment (66%) did. Patients who received nondelayed treatment demonstrated significant improvement in manual muscle testing 8 at the 12-month intervals (P < 0.001). Average serum CK values of all patients measured at the 3, 6, and 12 months did not significantly differ between the groups with nondelayed and delayed treatment. TIS improved more in the group with nondelayed treatment than in the group with delayed treatment (P = 0.002 at 3 months, P = 0.019 at 6 months, and P = 0.001 at 12 months). Seven patients in the group with delayed treatment had permanent residual muscle weakness requiring walker or wheelchair use at 12 months, whereas none of the patients in the group with nondelayed treatment did. CONCLUSION: Though our results have limitations, they contribute to a growing body of evidence that suggests that IVIG may prove to be a valuable addition to an early and aggressive induction regimen in patients afflicted by anti-HMGCRIMNM, particularly those with moderate to severe weakness requiring the use of a wheelchair or walking aids. Delay in IVIG treatment may lead to the development of permanent residual weakness and long-term disability.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Sharf K, Do T, Ghetie D, et al. Benefits of Early Versus Late Initiation of Intravenous Immunoglobulin in the Treatment of Patients With Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Immune-Mediated Necrotizing Myopathy. Arthritis Care Res (Hoboken). 2024. PMID: 39054727. doi:10.1002/acr.25406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。